

Amendments to the Claims

The listing of claims will replace all prior versions, and listing of claims in the application.

Listing of Claims

1-12. (Canceled).

13. (Currently Amended) A method of treating or preventing an affective disorder which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a bupropion metabolite, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, wherein the affective disorder is alcohol addiction, an anxiety disorder, ~~attention deficit disorder~~, a bipolar or manic condition, bulimia, chronic fatigue syndrome, narcolepsy, seasonal affective disorder, ~~or premenstrual syndrome, or weight gain~~.

14. (Original) The method of claim 13 wherein the bupropion metabolite is optically pure.

15. (Currently Amended) The method of claim 14 wherein the optically pure bupropion metabolite is optically pure (S,S)-2-(3-chlorophenyl)-2-hydroxy-3,5,5-trimethyl-morpholinol.

16-57. (Canceled).

58. (Currently Amended) The method of claim 14 wherein the optically pure bupropion metabolite is (R,R)-2-(3-chlorophenyl)-2-hydroxy-3,5,5-trimethyl-morpholinol; (S,S)-2-(3-chlorophenyl)-2-hydroxy-3,5,5-trimethyl- morpholinol; (R,R)-2-(*tert*-butylamino)-1-(3-chlorophenyl)-propan-1-ol; (S,R)-2-(*tert*-butylamino)-1-(3-chlorophenyl)-propan-1-ol; (S,S)-2-(*tert*-butylamino)-1-(3-chlorophenyl)-propan-1-ol; (R,S)-2-(*tert*-butylamino)-1-(3-chlorophenyl)-propan-1-ol; (R)-1-(3-chlorophenyl)-2-[(1,1-dimethylethanol)amino]-1-propanone; or (R)-1-(3-chlorophenyl)-2-[(1,1-dimethylethanol)amino]-1-propanone.

59. (Previously Presented) The method of claim 13 wherein adverse effects associated with the administration of racemic bupropion are reduced or avoided.

60. (Currently Amended) A method of treating or preventing nicotine addiction which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of (S,S)-2-(3-chlorophenyl)-2-hydroxy-3,5,5-trimethyl- morpholinol, or a pharmaceutically acceptable salt, solvate, or clathrate thereof.

61. (New) The method of claim 13 wherein the effective amount of the bupropion metabolite is from about 1 mg to about 750 mg per day.

62. (New) The method of claim 13 wherein the effective amount of the bupropion metabolite is from about 5 mg to about 700 mg per day.

63. (New) The method of claim 13 wherein the effective amount of the bupropion metabolite is from about 10 mg to about 650 mg per day.

64. (New) The method of claim 13 wherein the bupropion metabolite is administered orally, transdermally, and mucosally.

65. (New) The method of claim 64 wherein the bupropion metabolite is administered orally.

66. (New) The method of claim 64 wherein the bupropion metabolite is administered transdermally.

67. (New) The method of claim 64 wherein the bupropion metabolite is administered mucosally.

68. (New) The method of claim 13 wherein the affective disorder is alcohol addiction.

69. (New) The method of claim 13 wherein the affective disorder is an anxiety disorder.

70. (New) The method of claim 13 wherein the affective disorder is a bipolar or manic condition.

71. (New) The method of claim 13 wherein the affective disorder is bulimia.

72. (New) The method of claim 13 wherein the affective disorder is chronic fatigue syndrome.

73. (New) The method of claim 13 wherein the affective disorder is narcolepsy.


74. (New) The method of claim 13 wherein the affective disorder is seasonal affective disorder.

75. (New) The method of claim 13 wherein the affective disorder is premenstrual syndrome.

76. (New) The method of claim 13 wherein the bupropion metabolite is in the form of an acceptable salt.

77. (New) The method of claim 13 wherein the bupropion metabolite is in the form of a solvate.

78. (New) The method of claim 13 wherein the bupropion metabolite is:



or a mixture thereof.